A5071166698- Advanced Breast Cancer Therapies
- Cancer survivorship and care
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Salivary Gland Disorders and Functions
- Global Cancer Incidence and Screening
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Medication Adherence and Compliance
- Metabolomics and Mass Spectrometry Studies
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Advanced Chemical Sensor Technologies
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Curcumin's Biomedical Applications
- RNA Interference and Gene Delivery
- Salivary Gland Tumors Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer Risks and Factors
Hospital Sírio-Libanês
2016-2025
University Center of Brasília
2023
Fundação de Apoio a Pesquisa do Estado de Goiás
2023
Sociedade Brasileira de Oncologia Clínica
2023
Universidade de Brasília
2016-2021
Instituto Nacional do Câncer
2007
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have been recently developed and introduced into clinical practice. We retrospectively analyzed data from patients with confirmed HR+/HER2 metastatic breast cancer treated hormonal therapy in combination ribociclib (R), palbociclib (P), or abemaciclib (A). Outcomes: median progression-free survival (mPFS), time to treatment discontinuation (mTTD), objective response rate (ORR). Between January 2016 - June 2021, 142 were an CDK4/6i (79 P, 42 R,...
Brazil is the largest country in South America and most genetically heterogeneous. The aim of present study was to determine prevalence germline pathogenic variants (PVs) Brazilian patients with breast cancer (BC) who underwent genetic counseling testing at a tertiary Oncology Center. We performed retrospective analysis medical records BC referred between August 2017 2019. A total 224 unrelated were included this study. Premenopausal women represented 68.7% cohort. median age diagnosis 45...
PURPOSE Cyclin inhibitors plus endocrine therapy represent the reference standard for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) locally advanced or metastatic breast cancer (ABC). Efficacy results on hard end points such as overall survival come from well-designed randomized clinical trials (RCTs). However, a limitation of RCTs is low external validity, and their extrapolation to broader population may not be appropriate. Real-world studies can...
PURPOSE Adjuvant endocrine therapy (ET) improves the prognosis of patients with nonmetastatic estrogen receptor–positive (ER+) breast carcinoma; however, adherence is crucial to ensure its efficacy. In Brazil, data regarding ET are limited. We aimed evaluate across Brazil and characteristics associated adherence. METHODS Women ER+ invasive carcinoma who underwent for at least 6 months were enrolled. Adherence was assessed using Morisky Medication Scale-8 (MMAS-8) defined as an MMAS-8 score...
PURPOSE There are no available data concerning gender equity and workplace mistreatment within the field of oncology in Brazil. The Brazilian Society Clinical Oncology (Sociedade Brasileira de Oncologia Clínica [SBOC]) performed a survey study to present discuss this subject gain insights into strategies that would mitigate inequities. MATERIALS AND METHODS A 24-question Portuguese, assessing demographics, professional context, achievements, mistreatment, parenthood, balance workplace, was...
609 Background: The KEYNOTE-522 regimen (neoadjuvant pembrolizumab combined with a four-drug chemotherapy backbone, followed by adjuvant pembrolizumab) is standard of care for stage II-III triple-negative breast cancer (TNBC). However, the median age TNBC diagnosis 40–50 years, and elderly patients (pts) are underrepresented in clinical trials. Methods: effectiveness safety were evaluated aged ≥65 years (y) Neo-Real/GBECAM-0123 trial, real-world, multicenter study conducted across ten...
e12618 Background: Triple-negative breast cancer (TNBC) is the most immunogenic subtype and highly prevalent among patients (pts) with germline BRCA1/2 mutations (gBRCAm). Regardless of mutation status, current standard treatment for early-stage TNBC chemotherapy combined pembrolizumab, as per KEYNOTE-522 protocol. Methods: Data were collected from pts diagnosed treated according to regimen at ten centers July 2020 December 2024. Epidemiological data outcomes gBRCAm compared those BRCA...
Metabolic alterations are a hallmark of the malignant transformation in cancer cells, which is characterized by multiple changes metabolic pathways that linked to macromolecule synthesis. This study aimed explore whether salivary metabolites could help discriminate between breast patients and healthy controls. Saliva samples from 23 35 controls were subjected untargeted metabolomics using liquid chromatography-quadrupole time-of-flight mass spectrometry bioinformatics tool (XCMS Online),...
The early detection of breast cancer enables the use less aggressive treatment and increases patient survival. transmembrane glycoprotein mucin 1, which is also known as antigen 15-3 (CA15-3), aberrantly glycosylated overexpressed in a variety epithelial cancers, serves crucial role progression disease. CA15-3 currently used marker cancer. In present study, concentrations saliva blood patients with were evaluated to test new assays detect salivary addition ELISA its diagnostic value. To best...
Linfomas são transformações neoplásicas de células linfóides normais que residem predominantemente em tecidos linfóides. O linfoma não-Hodgkin (LNH) é a quarta neoplasia mais incidente nos Estados Unidos, excluindo o câncer pele não-melanoma, e também nona causa morte por no sexo masculino sétima feminino, envolvido 5% das mortes câncer. Os linfomas alto grau responsáveis cerca 50% todos os casos LNH englobam difuso grandes B, folicular pouco diferenciado, do manto, T periférico anaplásico....
The current pandemic moment of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has completely changed health services, with most services being directed to the treatment affected patients. Even during this critical period, cancer patients need be treated, as delayed can compromise chances a cure. Brazilian Society Clinical Oncology (SBOC) developed recommendations guide decisions in breast SARS-CoV-2 through their Breast Tumors Committee. Due scarcity relevant data, discussions...
Malignant mixed müllerian tumor (MMMT) is a rare neoplasm, consisting of carcinomatous (epithelial) and sarcomatous (mesenchymal) components that most commonly arise in the endometrium more infrequently ovaries, fallopian tube, cervix, vagina. Primary peritoneal carcinosarcoma (PPCS) an extremely extragenital presentation MMMT. Although occurrence breast cancer epithelial ovarian carcinoma association with
540 Background: In the MonarchE and Natalee studies, most patients received (neo)adjuvant chemotherapy (CT). precision oncology era, genomic signatures such as Oncotype DX (ODX) can spare many of CT. Our recent Real-World data (RWD) showed that a proportion with hormone receptor positive (HR+) HER2 negative (HER2-) early breast cancer (eBC) would be eligible for adjuvant abemaciclib or ribociclib without indication The main question addressed in this analysis is potential benefit CDK4/6i...
e12629 Background: Triple-negative breast cancer (TNBC) prognosis is significantly influenced by tumor-infiltrating lymphocytes (TILs), but the lack of validated cutoff values has limited their clinical applicability. In era neoadjuvant pembrolizumab plus chemotherapy (P+CT) as a new standard care, role TILs predictors response to chemoimmunotherapy remains uncertain. Methods: This study aimed assess pathologic complete (pCR) within Neo-Real study, multicenter, real-world data investigation...
Oncotype DX (ODX) is a validated assay for the prediction of risk recurrence and benefit chemotherapy (CT) in both node negative (N0) 1-3 positive nodes (N1), hormone receptor (HR+), human epidermal growth factor 2-negative (HER2-) early breast cancer (eBC). Due to limited access genomic assays Brazil, treatment decisions remain largely driven by traditional clinicopathologic factors. ODX has been reported be cost-effective different health system, but data are available considering reality...